

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[About Us](#)
[Sloan Kettering Institute](#)
[The Jan Grimm Lab](#)


[Research](#)


Prostate Cancer Imaging & Prostate-Specific Membrane Antigen (PSMA)

[Education & Training](#)

[News & Events](#)

[Open Positions](#)





The antibody 7E11 binds to the intracellular epitope of PSMA and can reach this only when the cell membrane is damaged. In this case, the tumor on the right was irradiated; the left one was not. The irradiated tumor demonstrates higher 7E11 binding (here labeled with Cy5.5) in this maximum-intensity projection of an optical tomography dataset.

PSMA is a dimeric type II integral membrane glycoprotein, highly expressed on prostate cancer cells. It has been shown to be a predictor for prostate cancer progression and for prognosis of prostate cancer. For example, elevated PSMA levels are seen in aggressive forms of the disease, i.e., metastatic and higher-grade prostate cancers. High-level PSMA expression is correlated with early PSA recurrence in surgically treated prostate cancer. PSMA correlates with the aggressiveness of the disease, and thereby strongly support PSMA as an excellent target for prostate cancer characterization and subsequent therapy.

Our lab is interested in using nanoparticles as nanocarriers for drugs to improve prostate cancer therapy and small molecular agents to quantify PSMA expression in vivo. Many of our agents, described in the other projects (nanoagents and activatable imaging agents), are geared toward PSMA. Beyond that, we have a particular interest in the biological and enzymatic function of PSMA as it pertains to tumor promotion and vascularization.

We are further exploring ways to better characterize sentinel lymph nodes in prostate as well as in other cancers (e.g., endometrial and breast). We recently developed positron lymphography, a concept that is being expanded currently in the lab.

[Thorek D, Abou D, Beattie B, Bartlett R, Huang R, Zanzonico P, Grimm J. "Positron Lymphography: Multimodal, High-Resolution, Dynamic Mapping and Resection of Lymph Nodes After Intradermal Injection of 18F-FDG." JNM 2012; 53\(9\):1438.](#)

[Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova, A, Bander N, Lewis JS, Grimm J \(2011\) Targeting the internal epitope of prostate-specific membrane antigen with ⁸⁹Zr-7E11. J Nuclear Med 52\(10\):1608-15.](#)

Project Members

[Anuja Ogirala](#)

PREVIOUS

[Smart Imaging Agents](#)

NEXT

[Cerenkov Imaging](#)

[Overview](#)

[Leadership](#)

[Administration](#)

[History](#)

[Contact Us](#)



▾ Research

[Overview](#)

[Research programs](#)

[Research labs](#)

[Core facilities & resources](#)

▾ Education & Training

[Overview](#)

[Postdoctoral training](#)

[Gerstner Sloan Kettering Graduate School](#)

[Joint graduate programs](#)

[Programs for college & high school students](#)

▾ News & Events

[Overview](#)

[Seminars & events](#)

▾ Open Positions

[Overview](#)

[Faculty positions](#)

[Postdoctoral positions](#)

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center